Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m sure everyone wants to know the timing for interim results.
But a month earlier it WAS deemed in sh interests. And they might change their mind again ? The rs *ought* to have been based on the strength of the yet to be released mono data. I now have doubts about that. Or serious doubts about mgmt decision making abilities. Either way is bad.
Thanks nt2, for addressing my question, even tho you clicked on Marty’s post.
This is an honest question : why would the fda NOT want CYDY to release trial data ? As long as it’s accurate, why should they care ?
Hopefully a humorous comment : I think the real reason CYDY has had difficulties is the lack of a stupid acronym name for their clinical trials. If they had them, things would be going smoothly.
Ok thanks, trding !
What press release is Nader talking about ? Was he just making this up ? Or was it an old release ?
If the reaction to that news is twice as good as the p.e. announcement, then we won’t move north of $1. That’s as optimistic as I can get OTC.
That strategy hasn’t helped me any. I guess I will start being optimistic.
Would that be fiction or historical documentary ?
Glad you guys were able to profit, though.
Not for me. Tried to take advantage of swings twice, and I lost a tiny bit.
The entire MARKET forgets these things. Because this is a penny pink sheet bulletin board stock. That might not change until buyout.
Again, thanks for sharing, Saltz. I have a glass half-empty take.
Wasn’t the news to accompany the r/s to be the interim results ? Was there a delay in that or did it turn out to be less than expected ? Or will that be released anyway in a week or two ?
Nader mentioned doctor statements on the pr. That wasn’t on today’s or Mondays pr. Where did that come from ?
Close to the finish line ? Ahem, I heard that in 2016.
If FDA were going to issue BTD, it would have been awhile ago. Optimistic assumption.
I did not get the sense that things will wrap up soon from this letter.
By pivotal, you mean that Mono would be first to approve, right ? But how can that be, when they aren’t even close to 300 for the safety portion ?
So how far does bureaucratic stupidity go ? Littlefinger’s dictum might suggest it is otherwise.
Ok, thanks gestalt !
I don’t think BTD is going to happen; rarely is one issued this far along the review process. Which metric is substantially better than SOC ?
2 things : what press release has those Dr quotes, and why on earth would they issue 200 Mill shares ?
I’m sure that their 6 employees can handle it.
We KNOW that mono enrollment is delayed. Otherwise why would they open a few new sites if they were remotely close to 300. But that doesn’t explain why they thought the split was going to happen, then changed their minds. I felt in my gut it was a mistake to announce the split 5 weeks early. So much can happen in that time....and something did. A buyout now ? Miserable timing. A GvHD partner ? I’ve No idea, really.
The stock went up 40% before the p.e. announcement. Stocks are traded on insider info all the time. That doesn’t mean every movement is due to that. The sell off is severe because this issue is so thinly traded. It’s so thinly traded because it’s on otc. That will change when a 100 times more investors have an opportunity to come here.
The number of bearish posts that make no sense at all are increasing. I take that as a bullish sign.
When would you say is the last possible time a buyout could be ? That is my suspicion.
The only “new” news that I saw is that a few patients dropped out of the mono rollover trial.
The important question is : Is anyone paying attention ?
We will find out in a couple weeks. Presumably there are plenty of buyers waiting after uplisting. If not, there is some giant dilution in store.
34%
Presuming we fall to 40 cents before the PRs begin, the shorts would only need to knock the price down another 30% in order to prevent the uplist. Theoretically. They and the market as a whole would have to be a bunch or morons for that to happen.
Thank you ! That reassures me that I will be able to get cheap shares at least until the PR is put out.
Clinical trials gov website was updated last month and says that it should have had primary completion for mono hiv trial. I would ignore it except that it was updated last month. They might have 150 patients at the 48 week mark at that point, but not 300. What gives ?
I hope to have more cash 6 trading days before we hit new lows. I don’t think that will happen. Who knows, It could be May before I would be able to buy more.
Yes and I agree with that so far, but barring some SAE, or bizarre conspiracy, CYDY’s Godot will show up. The company KNOWS the data in the trial, and it IS going to be made public. With 2 trials reaching endpoints (mono being interim so far) Godot is gonna show up. And it’s looking as sweet as Gal Godot !!
Thank you Bored. Of course we don’t *know* until Apr 17ish, but that’s a more .... satisfying explanation.
So the reason why they didn’t just split in March was that they are still preparing whatever reports are necessary for the interim results ? And that takes a few weeks, presumably.
Why would the company announce a split one month ahead of time ? What sort of things (good news to accompany the r/s) might they know about that far in advance but not be able to release ?
No, I am merely suggesting the company continue raising in small increments again until valuations moderate.
Before we issue 50 Mill more shares !
And for a Phase 2 drug, no less.
At the current trend, we might be at 45 cents by split day. April 19. That’s just crazy cheap !
The Clinical Trials .gov website has March 2018 as the Mono HIV completion date. It was updated in March 2018. That has to be a typo. Maybe March 2019.